共激活因子在甲状腺肿瘤组织中的表达及其临床意义

The expression and clinical significance of amplified in breast cancer 1 protein in thyroid tumor tissues

目的探讨核受体共激活因子（AIB1）蛋白在甲状腺瘤、甲状腺癌中的表达情况，以及AIB1蛋白表达与甲状腺癌临床病理特征间的相关性。方法免疫组化SP法检测AIB1在97例甲状腺癌、32例甲状腺良性肿瘤与16例正常对照组织巾的表达，并分析AIB1蛋白表达与甲状腺癌患者组织类型与淋巴结转移等临床病理特征间相关性。结果AIB1表达的阳性率在甲状腺癌（81／97，83．51％）、甲状腺瘤组织（20／32，62．50％）中明显高于正常对照组织（2／16，12．50％），差异有统计学意义（χ^2=35．510和χ^2=10．741，均P〈0．001），其中以甲状腺癌表达最高，甲状腺瘤与甲状腺癌AIB1蛋白表达差异有统计学意义（χ^2=6．247，P〈0．012）。乳头状癌与滤泡状癌组织中AIB1蛋白表达差异无统计学意义（χ^2=1．340，P=0．512），但与淋巴结是否转移相关（χ^2=7．222，P〈0．027）。结论AIBI蛋白高表达可能参与甲状腺癌的发乍、发展。

Objective To investigate the expression and clinical significance of amplified in breast cancer 1 （ AIB1 ） protein in thyroid tumor. Methods Immunohistochemistry, was used to detect the expressions of AIB1 in 97 cases of thyroid carcinoma, 32 cases of thyroid adenoma and 16 cases normal tissues, then the correlation between expression and clinical features, including histological type, and lymphatic metastasis was analyze. Results Compared with the normal tissues（2/16,12.50% ） , the positive rates of AIB1 expressions were higher in thyroid carcinoma （ 81/97,83.51% ） and thyroid adenoma （ 20/32,62.50 % ） （ P 〈 0.001 ） and were the highest in thyroid carcinoma. There was a significant difference of AIB1 expressions between thyroid carcinoma and thyroid adenoma（χ^2 = 6. 247,P 〈 0.012）. For thyroid carcinoma, the expression of AIB1 was correlated with lymphatic metastasis （χ^2 = 7. 222,P 〈0. 027）, however, it was not correlated with histological type（χ^2 = 1. 340,P =0.512）. Conclusion The over expression o f AIB1 may be involved in the carcinogenesis and development of thyroid carcinoma.